Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Milestone Pharmaceuticals Inc.

Get SEC filing alerts via email and in your feed for Milestone Pharmaceuticals Inc.

MIST

Milestone Pharmaceuticals Inc.

About Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals develops innovative cardiovascular medicines, focusing on rapid-onset nasal spray treatments for arrhythmias like PSVT and AFib-RVR. Its flagship product, CARDAMYST (etripamil), aims to provide self-administered, fast-acting therapy for episodic heart rhythm disturbances. The company targets the U.S. and global markets, leveraging proprietary formulations, clinical data, and strategic partnerships to address unmet needs in acute cardiovascular care.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Milestone Pharmaceuticals Inc.

1
1
Milestone Pharmaceuticals Inc. Milestone Pharmaceuticals Reports $238,000 in Product Revenue and $26.1 Million Net Loss for Q1 2026

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
Milestone Pharmaceuticals Inc. Milestone Pharmaceuticals Reports $63.1 Million Net Loss and FDA Approval of CARDAMYST™

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Milestone Pharmaceuticals Inc. Milestone Pharmaceuticals Reports $11.9M Net Loss in Q3 2025, Prepares for Etripamil Launch

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Milestone Pharmaceuticals Inc. Milestone Pharmaceuticals Reports $12.97 Million Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Milestone Pharmaceuticals Inc. Milestone Pharmaceuticals Reports $20.8 Million Net Loss in Q1 2025, No Revenue Generated

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Milestone Pharmaceuticals Inc. Milestone Pharmaceuticals Reports $41.5 Million Net Loss for Fiscal Year 2024, No Revenue Generated

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Milestone Pharmaceuticals Inc. Milestone Pharmaceuticals Reports Improved Financials, Reduced Losses, and Increased Cash Reserves

Via official filing (AI summary) | over 1 year ago | 0 comments